Timcodar (VX-853) Is a Non-FKBP12 Binding Macrolide Derivative That Inhibits PPARγand Suppresses Adipogenesis
Open Access
- 1 January 2016
- journal article
- research article
- Published by Wiley in PPAR Research
- Vol. 2016, 1-10
Abstract
Nutrient overload and genetic factors have led to a worldwide epidemic of obesity that is the underlying cause of diabetes, atherosclerosis, and cardiovascular disease. In this study, we used macrolide drugs such as FK506, rapamycin, and macrolide derived, timcodar (VX-853), to determine their effects on lipid accumulation during adipogenesis. Rapamycin and FK506 bind to FK506-binding proteins (FKBPs), such as FKBP12, which causes suppression of the immune system and inhibition of mTOR. Rapamycin has been previously reported to inhibit the adipogenic process and lipid accumulation. However, rapamycin treatment in rodents caused immune suppression and glucose resistance, even though the mice lost weight. Here we show that timcodar (1 μM), a non-FKBP12-binding drug, significantly () inhibited lipid accumulation during adipogenesis. A comparison of the same concentration of timcodar (1 μM) and rapamycin (1 μM) showed that both are inhibitors of lipid accumulation during adipogenesis. Importantly, timcodar potently () suppressed transcriptional regulators of adipogenesis, PPARγand C/EBPα, resulting in the inhibition of genes involved in lipid accumulation. These studies set the stage for timcodar as a possible antiobesity therapy, which is rapidly emerging as a pandemic.
Keywords
Funding Information
- National Heart, Lung, and Blood Institute (K01HL125445, L32MD009154, HL106365)
- National Heart, Lung, and Blood Institute (K01HL125445, L32MD009154, HL106365)
- National Heart, Lung, and Blood Institute (K01HL125445, L32MD009154, HL106365)
This publication has 59 references indexed in Scilit:
- Resveratrol potentiates rapamycin to prevent hyperinsulinemia and obesity in male mice on high fat dietCell Death & Disease, 2013
- Protein Phosphatase 5 Mediates Lipid Metabolism through Reciprocal Control of Glucocorticoid Receptor and Peroxisome Proliferator-activated Receptor-γ (PPARγ)Journal of Biological Chemistry, 2011
- Discovery of Glucocorticoid Receptor-β in Mice with a Role in MetabolismMolecular Endocrinology, 2010
- Susceptibility to Diet-Induced Hepatic Steatosis and Glucocorticoid Resistance in FK506-Binding Protein 52-Deficient MiceEndocrinology, 2010
- FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin AOncogene, 2009
- Targeted ablation reveals a novel role of FKBP52 in gene-specific regulation of glucocorticoid receptor transcriptional activityThe Journal of Steroid Biochemistry and Molecular Biology, 2009
- FKBP immunophilin patents for neurological disordersExpert Opinion on Therapeutic Patents, 2005
- Calcineurin Mediates the Calcium-dependent Inhibition of Adipocyte Differentiation in 3T3-L1 CellsJournal of Biological Chemistry, 2002
- Molecular Mechanisms of Adipocyte Differentiation and Inhibitory Action of Pref-1Critical Reviews™ in Eukaryotic Gene Expression, 1997
- Inhibition of Adipogenesis Through MAP Kinase-Mediated Phosphorylation of PPARγScience, 1996